Invitrogen™ HMHA1 Polyclonal Antibody

Catalog No.	Quantity
PIPA5144069	100 μg

Catalog No. PIPA5144069 Supplier Invitrogen™ Supplier No. PA5144069

Description

Rabbit Polyclonal Antibody

Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL. Positive Control - WB: human Hela whole cell, human Raji whole cell, human A549 whole cell. IHC: human B lymphocytic tumor tissue. Flow: SiHa cell. Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domain which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

Specifications

• Antigen: HMHA1
• Applications: ELISA, Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot
• Classification: Polyclonal
• Concentration: 500 μg/mL
• Conjugate: Unconjugated
• Formulation: PBS with 4mg trehalose and no preservative
• Gene: ARHGAP45
• Gene Accession No.: Q92619
• Gene Alias: 6330406L22Rik; ARHGAP45; AW539505; Ha-1; histocompatibility (minor) HA-1; HLA-HA1; Hmha1; KIAA0223; mHag HA-1; Minor histocompatibility antigen HA-1; minor histocompatibility protein HA-1; minor histocompatibility protein HA-1; rho GTPase-activating protein 45; RGD1308662; Rho GTPase activating protein 45; rho GTPase-activating protein 45
• Gene Symbols: ARHGAP45
• Host Species: Rabbit
• Immunogen: E.coli-derived human ARHGAP45 recombinant protein (Position: D111-E349).
• Purification Method: Antigen affinity chromatography
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 23526
• Target Species: Human
• Content And Storage: -20°C
• Product Type: Antibody
• Form: Lyophilized
• Isotype: IgG